CX News 2017-08-10T16:03:39+00:00

CX NEWS

Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018

Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018 Ulf Teichgräber, Jena, Germany

“Promising” initial results for sirolimus-eluting bioresorbable scaffold in DESappear trial

Andrew Holden The sirolimus-eluting bioresorbable peripheral scaffold system (Prava; Elixir Medical) is designed to treat stenoses and occlusion in the superficial femoral artery. Prava was first implanted in October 2016 and will [...]

CX 2018: Landmark EVRA trial provides first Level 1 evidence for early endovenous ablation

The first full results of the Early Venous Reflux Ablation (EVRA) ulcer study were presented at the Charing Cross Symposium yesterday. The presentation was accompanied by simultaneous publication in the New England Journal of [...]

Majority of CX audience decides endovascular-first strategy for critical limb ischaemia is a concept without evidence

At the CX Great Debate held yesterday, vascular and endovascular surgery titans went head-to-head to debate the contentious topic “Endovascular-first strategy for critical limb ischaemia is a concept without evidence”. Arguing in favour of [...]